TITLE

New treatment option

AUTHOR(S)
Kondro, Wayne
PUB. DATE
July 2011
SOURCE
CMAJ: Canadian Medical Association Journal;7/12/2011, Vol. 183 Issue 10, pE654
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on the approval of the use of fidaxomicin tablets by the U.S. Food and Drug Administration (FDA) for treating Clostridium difficile-associated diarrhea.
ACCESSION #
64630970

 

Related Articles

  • Rebiotix Receives Breakthrough Therapy Designation for RBX2660 for the Treatment of Recurrent Clostridium difficile Infection.  // Clinical Infectious Diseases;1/1/2016, Vol. 62 Issue 1, pi 

    The article reports on the biotechnology firm Rebiotix Inc.'s Microbiota Restoration Therapy (MRT) RBX2660 that has been designated as a Breakthrough Therapy for the treatment of recurrent Clostridium difficile infection (CDI), by the U.S. Food and Drug Administration (FDA).

  • Fidaxomicin: Cost Considerations for the Treatment of Clostridium difficile Infection. Song, Jessica C.; Hsiao, Paul; Tran, Stephanie // Infectious Disease Alert;Sep2011, Vol. 30 Issue 12, p133 

    The article reports on the approval of fidaxomicin by the U.S. Food and Drug Administration (FDA) for the treatment of Clostridium difficile infection (CDI). It cites the development of clinical practice guidelines for CDI by the Society for Healthcare Epidemiology of America (SHEA) and the...

  • Is Fidaxomicin Worth the Cost? An Economic Analysis. Bartsch, Sarah M.; Umscheid, Craig A.; Fishman, Neil; Lee, Bruce Y. // Clinical Infectious Diseases;Aug2013, Vol. 57 Issue 4, p555 

    Our model suggests that when approximately 50% of isolates are NAP1/BI/027, fidaxomicin use for Clostridium difficile infection is not cost-effective at its current cost. However, typing and treatment with fidaxomicin based on strain may be more promising depending on its costs.Background. In...

  • Treatment of relapsing Clostridium difficile infection using fecal microbiota transplantation. Pathak, Rahul; Enuh, Hill Ambrose; Patel, Anish; Wickremesinghe, Prasanna // Clinical & Experimental Gastroenterology;2013, Vol. 7, p1 

    Background: Clostridium difficile infection (CDI) has become a global concern over the last decade. In the United States, CDI escalated in incidence from 1996 to 2005 from 31 to 64/100,000. In 2010, there were 500,000 cases of CDI with an estimated mortality up to 20,000 cases a year. The...

  • Fecal transplantation poses dilemma for FDA. Ratner, Mark // Nature Biotechnology;May2014, Vol. 32 Issue 5, p401 

    The article focuses on the plan of the U.S. Food and Drug Administration to tighten its supervision of the fecal microbiota transplants (FMTs). It states that the agency will draw back its decision to exempt companies and doctors from filing an investigational new drug (IND) application when...

  • The DIY gut-bug swap. Hamzelou, Jessica // New Scientist;3/1/2014, Vol. 221 Issue 2958, p10 

    The article discusses faecal microbiota transplantation (FMT), focusing on the home application of the treatment by people in the U.S. and Canada where regulations restrict official administration of the procedure. Topics include the technique's reported effectiveness in treating Clostridium...

  • Optimer Pharmaceuticals Buoyed by Unanimous Vote. Serebrov, Mari // BioWorld Today;4/6/2011, Vol. 22 Issue 66, p1 

    This article reports that an advisory committee of the U.S. Food and Drug Administration (FDA) has unanimously recommended the approval of Optimer Pharmaceutical Incorporated's Dificid as a treatment for Clostridium difficile infection. According to Optimer President and Chief Executive Officer...

  • ViroPharma Loses Vancocin Try; FDA Panel Vote Favors Generics. Young, Donna // BioWorld Today;8/5/2009, Vol. 20 Issue 149, p1 

    The article reports on the unanimous vote of a U.S. Food and Drug Administration (FDA) panel of outside experts to allow makers of generic versions of vancomycin to use in vitro dissolution testing to demonstrate bioequivalence for products containing the same ingredients as that of Vancocin,...

  • Sales of Optimer's Inaugural Drug Off to Stellar Start. QUIGLEY, KELLY // San Diego Business Journal;9/19/2011, Vol. 32 Issue 38, p1 

    The article on the new approved drug Dificid from Optimer Pharmaceuticals Inc. for the treatment of Clostridium difficle-associated diarrhea (CDAD), and its sales since in first entry in drug market. According to company's chief executive officer (CEO), Pedro Lichtinger, the said drug has...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics